Pathological Hypersexuality Induced by Dopamine Replacement Therapy in a Patient with Progressive Supranuclear Palsy

摘要

To the Editor: The pathogenesis of pathological hypersexuality is still in controversy. To our knowledge, this is the first report of pathological hypersexuality induced by two different dopamine receptor agonists in a single patient with progressive supranuclear palsy. In this case, dopamine D2 receptor agon-ism, perhaps specifically D3 receptor subclass agonism, might have played a key role in the development of pathological hypersexuality induced by dopamine replacement therapy.was normal (2.3 ng/ml), whereas serum prolactin level was suppressed to 1.3 ng/ml.His pathological hypersexuality completely disappeared 2 weeks after discontinuation of bromocriptine. After 4 weeks, pramipexole (0.125 mg b.i.d.), another dopamine receptor agonist, was added instead of bromocriptine since his motor performance deteriorated. After 1 week of pramipexole, all the hyper-sexual symptoms reemerged. At this point, his serum prolactin level was 2.2 ng/ml.